CLRB Share Price | Cellectar Biosciences, Inc. Stock Analysis & Recommendation

Q: How big is Cellectar Biosciences, Inc.?

Market Cap: As of Jun 18, Cellectar Biosciences, Inc. has a market capitalization of 16.19 million, classifying it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Cellectar Biosciences, Inc. reported net sales of 0.00 million and a net profit of -24.54 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 15.68 million and total assets of 25.47 million.

Q: What does Cellectar Biosciences, Inc. do?

Overview:Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot:Most recent Net Profit: -7 Million (Quarterly Results - Mar 2025) Market cap: USD 16.19 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.43 Return on Equity: -549.62% Price to Book: 1.68Contact Details:Address: 100 Campus Dr, FLORHAM PARK NJ: 07932-1020 Tel: 1 608 4418120 Fax: 1 608 4418121 Website: http://cellectar.com

Q: Who are in the management team of Cellectar Biosciences, Inc.?

As of March 2022, the management team of Cellectar Biosciences, Inc. includes the following individuals:- Mr. Douglas Swirsky, who serves as the Independent Chairman of the Board.- Mr. James Caruso, who is the President, Chief Executive Officer, and Director.- Mr. Frederick Driscoll, who is an Independent Director.- Dr. Stephen Hill, who is also an Independent Director.- Mr. Stefan Loren, serving as an Independent Director.- Mr. John Neis, who is another Independent Director.In summary, the management team consists of a mix of independent directors and key executives, highlighting a structured leadership approach.

Q: Is Cellectar Biosciences, Inc. technically bullish or bearish?

As of 8 September 2025, the technical trend for Cellectar Biosciences, Inc. has changed from mildly bullish to bullish. The current stance is bullish, with key indicators supporting this view being the weekly and monthly RSI readings, both of which are bullish. However, the MACD remains mildly bullish on both weekly and monthly time frames, indicating some caution. The Dow Theory shows a mixed picture with a mildly bullish weekly signal but a bearish monthly signal. Despite the bullish trend, the stock has underperformed significantly compared to the S&P 500 over various periods, with a 1-year return of -91.29% versus the S&P 500's 17.14%, and a staggering 5-year return of -98.49% compared to the S&P 500's 96.61%. This suggests that while the current technical indicators are bullish, the overall performance remains weak relative to the benchmark.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

37.8 k

Shareholding (Sep 2025)

FII

5.03%

Held by 11 FIIs

DII

91.68%

Held by 3 DIIs

Promoter

0.00%

How big is Cellectar Biosciences, Inc.?

22-Jun-2025

As of Jun 18, Cellectar Biosciences, Inc. has a market capitalization of 16.19 million, classifying it as a Micro Cap company, with net sales of 0.00 million and a net profit of -24.54 million over the latest four quarters. The company reported shareholder's funds of 15.68 million and total assets of 25.47 million as of Dec 24.

View full answer

What does Cellectar Biosciences, Inc. do?

22-Jun-2025

Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer treatments, with a market cap of $16.19 million and a recent net profit loss of $7 million. The company operates in the Pharmaceuticals & Biotechnology industry and has no dividend yield.

View full answer

Who are in the management team of Cellectar Biosciences, Inc.?

22-Jun-2025

As of March 2022, Cellectar Biosciences, Inc.'s management team includes Mr. Douglas Swirsky (Independent Chairman), Mr. James Caruso (President and CEO), and five Independent Directors: Mr. Frederick Driscoll, Dr. Stephen Hill, Mr. Stefan Loren, and Mr. John Neis. This team combines key executives with independent oversight for structured leadership.

View full answer

Is Cellectar Biosciences, Inc. technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, Cellectar Biosciences, Inc. shows a bullish trend supported by positive RSI readings, though it has significantly underperformed the S&P 500 with a 1-year return of -91.29% and a 5-year return of -98.49%.

View full answer

Compare Cellectar Biosciences, Inc. with Similar Stocks

Qilian International Holding Group Ltd.Corbus Pharmaceuticals Holdings, Inc.ARCA biopharma, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 10 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.33

Return on Equity

-314.72%

Price to Book

1.04

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2025)

Net Profit:

-4 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-10.75%

6 Months

-40.91%

1 Year

-61.67%

2 Years

-97.35%

3 Years

81.21%

4 Years

-98.25%

5 Years

43.75%

Cellectar Biosciences, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-189.66%

EBIT to Interest (avg)

-28.39

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.43

Sales to Capital Employed (avg)

Tax Ratio

0.18%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

22.52%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.73

EV to EBIT

-0.06

EV to EBITDA

-0.06

EV to Capital Employed

-0.67

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-549.62%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bullish

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 4 Schemes (3.29%)

Foreign Institutions

Held by 11 Foreign Institutions (5.03%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 70.07% vs -7.30% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.80",
          "val2": "-13.30",
          "chgp": "63.91%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.30",
          "val2": "6.10",
          "chgp": "-95.08%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.40",
          "val2": "-14.70",
          "chgp": "70.07%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -4.21% vs -34.59% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-51.50",
          "val2": "-38.80",
          "chgp": "-32.73%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "13.80",
          "val2": "-3.80",
          "chgp": "463.16%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-44.60",
          "val2": "-42.80",
          "chgp": "-4.21%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Sep'25

Sep'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-4.80

-13.30

63.91%

Interest

0.00

Exceptional Items

0.30

6.10

-95.08%

Consolidate Net Profit

-4.40

-14.70

70.07%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is 70.07% vs -7.30% in Sep 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-51.50

-38.80

-32.73%

Interest

0.00

Exceptional Items

13.80

-3.80

463.16%

Consolidate Net Profit

-44.60

-42.80

-4.21%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -4.21% vs -34.59% in Dec 2023

All Annual Results

Company CV

About Cellectar Biosciences, Inc.

Cellectar Biosciences, Inc.

Pharmaceuticals & Biotechnology

Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. The Company’s research and development program is based on its PDC cancer-targeting delivery platform. Its pipeline consists of pre-clinical and clinical product candidates, including radiotherapeutic and chemotherapeutic PDC's. Its PDC therapeutic, CLR 131 is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells. The Company’s product pipeline also includes one preclinical PDC chemotherapeutic program (CLR 1900). The CLR 1900 Series is targeted for solid tumors with a payload that inhibits mitosis a validated pathway for treating cancers.

Company Coordinates

Company Details

100 Campus Dr , FLORHAM PARK NJ : 07932-1020

Tel: 1 608 4418120

http://cellectar.com

Registrar Details

Cellectar Biosciences, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Cellectar Biosciences, Inc.?

Watch in Real-Time

What does Cellectar Biosciences, Inc. do?

Who are in the management team of Cellectar Biosciences, Inc.?

Is Cellectar Biosciences, Inc. technically bullish or bearish?

Compare Cellectar Biosciences, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Cellectar Biosciences, Inc.

Company Coordinates